Therapeutic Response to PRRNT in a Rare Case of Metastatic Renal Neuroendocrine Carcinoma

Abstract

Neuroendocrine tumors (NETs) are a rare spectrum of neoplasms that are characterized by neuroendocrine and neural differentiation. The treatment can be challenging in view of the heterogeneity in differentiation and behavior. Primary renal origin NETs are rare and only a few cases have been reported in the literature. There is limited knowledge on their presentation and response to various lines of treatment. We report a case of a patient with a metastatic renal NET from a rare histological subtype of large cell neuroendocrine carcinoma, known to cause aggressive disease with poor prognosis. A multimodality treatment approach was followed. In spite of surgical management and second-line chemotherapy, the disease progressed. The patient subsequently received peptide receptor radionuclide therapy (PRRNT) using lutetium-177 DOTATATE, following which the patient demonstrated a remarkable clinical and radiological response and is stable to date. In a rare tumor with poor prognosis, the relevance of theranostics and the efficacy of targeted therapies like PRRNT are noteworthy.

Keywords

neuroendocrine tumors - peptide receptor radionuclide therapy - theranostics - lutetium-177 - DOTATATE

Authors' Contribution

S.S.S. contributed to the planning, acquisition of data, literature search, reporting, and interpretation of data. H.J. contributed to the conception and design, acquisition and interpretation of data, guide, and review of the manuscript. K.T.A. contributed to data collection, technical support, review of manuscript, and critical revision, provided guidance. C.R. contributed to the review of the manuscript and critical revision and provided guidance.

Publikationsverlauf

Artikel online veröffentlicht:
09. April 2024

• References

• 1 Kim JY, Hong S-M, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol 2017; 29 (29) 11-16
• 2 DeLellis RA, Osamura RY. Neuroendocrine tumors: an overview. AJSP Rev Rep 2006; 11: 229-234
• 3 Lane BR, Jour G, Zhou M. Renal neuroendocrine tumors. Indian J Urol 2009; 25 (02) 155-160
• 4 Romero FR, Rais-Bahrami S, Permpongkosol S, Fine SW, Kohanim S, Jarrett TW. Primary carcinoid tumors of the kidney. J Urol 2006; 176 (6, Pt 1): 2359-2366
• 5 Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol 2016; 70 (01) 93-105
• 6 Lane BR, Chery F, Jour G. et al. Renal neuroendocrine tumours: a clinicopathological study. BJU Int 2007; 100 (05) 1030-1035
• 7 Martignoni G, Pea M, Brunelli M. et al. CD10 is expressed in a subset of chromophobe renal cell carcinomas. Mod Pathol 2004; 17 (12) 1455-1463
• 8 Kim B, Kim H-S, Moon KC. Primary renal well-differentiated neuroendocrine tumors: report of six cases with an emphasis on the Ki-67 index and mitosis. Diagn Pathol 2019; 14 (01) 12
• 9 Bodei L, Weber WA. Somatostatin receptor imaging of neuroendocrine tumors: from agonists to antagonists. J Nucl Med 2018; 59 (06) 907-908
• 10 van Essen M, Krenning EP, Kam BLR, de Jong M, Valkema R, Kwekkeboom DJ. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 2009; 5 (07) 382-393
• 11 Hasteh F, Pu R, Michael CW. A metastatic renal carcinoid tumor presenting as breast mass: a diagnostic dilemma. Diagn Cytopathol 2007; 35 (05) 306-310
• 12 Korkmaz T, Seber S, Yavuzer D, Gumus M, Turhal NS. Primary renal carcinoid: treatment and prognosis. Crit Rev Oncol Hematol 2013; 87 (03) 256-264
• 13 Rinke A, Müller H-H, Schade-Brittinger C. et al; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009; 27 (28) 4656-4663
• 14 Capello A, Krenning EP, Breeman WAP, Bernard BF, de Jong M. Peptide receptor radionuclide therapy in vitro using [¹¹¹In-DTPA0]octreotide. J Nucl Med 2003; 44 (01) 98-104
• 15 Strosberg J, El-Haddad G, Wolin E. et al; NETTER-1 Trial Investigators. Phase 3 trial of ¹⁷⁷Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 2017; 376 (02) 125-135
• 16 Shimbori M, Osaka K, Kawahara T. et al. Large cell neuroendocrine carcinoma of the kidney with cardiac metastasis: a case report. J Med Case Rep 2017; 11 (01) 297